6533b859fe1ef96bd12b8259
RESEARCH PRODUCT
Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.
Rosario MenéndezRosario MenéndezPaula González-jiménezRicardo AlonsoRaúl MéndezMarta SuescunJordi AlmirallSoledad ReyesAntoni TorresPedro Pablo EspañaLuis Martínez DolzIrene AldásIrene Aldássubject
Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyTime Factorsmedicine.drug_classCritical Care and Intensive Care MedicineRisk AssessmentProcalcitonin03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineNatriuretic peptidePneumonia BacterialMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedAged 80 and overbiologyTroponin Tbusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseTroponinCommunity-Acquired InfectionsPneumonia030228 respiratory systemCardiovascular Diseasesbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersdescription
Background Community-acquired pneumonia (CAP) increases the risk of cardiovascular complications during and following the episode. The goal of this study was to determine the usefulness of cardiovascular and inflammatory biomarkers for assessing the risk of early (within 30 days) or long-term (1-year follow-up) cardiovascular events. Methods A total of 730 hospitalized patients with CAP were prospectively followed up during 1 year. Cardiovascular (proadrenomedullin [proADM], pro-B-type natriuretic peptide (proBNP), proendothelin-1, and troponin T) and inflammatory (interleukin 6 [IL-6], C-reactive protein, and procalcitonin) biomarkers were measured on day 1, at day 4/5, and at day 30. Results Ninety-two patients developed an early event, and 67 developed a long-term event. Significantly higher initial levels of proADM, proendothelin-1, troponin, proBNP, and IL-6 were recorded in patients who developed cardiovascular events. Despite a decrease at day 4/5, levels remained steady until day 30 in those who developed late events. Biomarkers (days 1 and 30) independently predicted cardiovascular events adjusted for age, previous cardiac disease, Pa o 2/F io 2 Conclusions Cardiac biomarkers are useful for identifying patients with CAP at high risk for early and long-term cardiovascular events. They may aid personalized treatment optimization and for designing future interventional studies to reduce cardiovascular risk.
year | journal | country | edition | language |
---|---|---|---|---|
2019-04-18 | Chest |